- In October 2023, IP Group PLC announced a strategic development regarding their portfolio company, Celltech Biologics. The company revealed that Celltech Biologics has made significant progress in its advanced wound care treatments using biological materials. This development will enhance the production of skin substitutes derived from human tissues, helping to treat chronic and complex wounds more effectively. The partnership and technological advancements are expected to drive growth in the wound skin substitutes market by offering innovative solutions for patients with severe wounds. It will benefit the market by improving healing rates, lowering the cost of treatments, and expanding product accessibility
- In May 2023, BioTissue announced a new partnership with Dakota Lions Sight & Health to expand their birth tissue donation program. This collaboration aims to increase the availability of birth tissue for use in various medical treatments, particularly in wound care, by promoting awareness and facilitating easier donation processes. The development is expected to enhance the supply of biological materials, which are used in advanced wound care products such as skin substitutes. This partnership will positively impact the wound skin substitutes market by improving product accessibility, reducing costs, and supporting faster healing processes for patients with chronic wounds
